Home Special Topics Technology Offerings Content

Purin-Ago: Non-nucleotide agonists of the P2Y11-receptor with immunosuppressant effect

next article

08.02.2008

Purinergic receptors have been in the focus of drug discovery for many years. This invention provides nonnucleotide agonists of the P2Y11-receptor. The agonists ensure high specificity among P2-receptors which is a key to tolerability of compounds meant for applications in longterm treatment settings. Activation of the P2Y11-receptor leads to a variety of effects in the modulation of immune system activity. For example release of immune modulatory thrombospondin-1 is induced, while lipopolysaccharide (LPS)-stimulated release of the pro-inflammatory cytokine interleukin-12 (IL- 12) is inhibited by activation of the P2Y11-receptor.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.

info@technologieallianz.de | Source: TechnologieAllianz e.V.
Further information: www.technologieallianz.de/angebote.php?sort=sag&id=1241&lang=en
www.technologieallianz.de

next article